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Objectives
At the conclusion of this session, the participant will be able to:
 Interpret revised testing guidance for newborns with possible 
congenital Zika virus infection.
 Discuss clinical evaluation of infants born to mothers with laboratory 
evidence of Zika virus infection.
 Outline outpatient management of infants with laboratory evidence of 
congenital Zika virus infection with and without abnormalities 
consistent with congenital Zika syndrome.
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Topics to be covered
 Background on the effects of Zika virus during pregnancy on the infant
 Updated recommendations for initial testing of infants born to mothers with 
laboratory evidence of Zika virus infection
– Infant diagnostic testing and interpretation
 Clinical Evaluation 
– Initial evaluation of all infants born to mothers with lab evidence of Zika




Zika Virus Infection in Pregnant Women
 Pregnant women can be infected:
• Through the bite of an infected Ae. 
aegypti or Ae. albopictus mosquito 
• Through sex with an infected partner
 If infected around conception
• Zika might present risk to fetus
 If infected during pregnancy
• Zika can be passed to the fetus during 
pregnancy or around the time of birth
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Brain Abnormalities Associated with







 Brain atrophy and asymmetry
 Enlargement of posterior fossa
 Ventriculomegaly
 Restricted middle cerebral artery flow






Karwowski MP, Nelson JM, Staples JE, et al. Zika Virus Disease: A CDC Update for Pediatric Health Care Providers. Pediatrics. 2016;137(5):e20160621
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Infants with Microcephaly* 
Note scattered intracranial 
calcifications
Note large ventricles 
and volume loss
Typical newborn head CT scan
*CT scan images 
courtesy of 







Adverse Outcomes and Zika Virus
 Linked to spontaneous abortion and stillbirth
 Evidence insufficient to confirm Zika virus as cause
 Other infant outcomes:
 Eye abnormalities 
 Hearing impairment and loss
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What CDC is Doing to Learn More
Collecting data for action
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US Zika Pregnancy Registry (USZPR)
 Involves collection of information on Zika-affected 
pregnancies and congenitally exposed infants up to 1 
year of age
 Allows monitoring for any adverse pregnancy and 
fetal/neonatal outcomes (e.g., microcephaly)
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Zika Active Pregnancy Surveillance System (ZAPSS)
 Similar to USZPR 
• Conducted in Puerto Rico 
• Data collection of congenitally exposed infants extended 
to 3 years of age
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Number of Pregnant Women Who May Be Affected
 Currently there are over 1,000 pregnant women with 
laboratory evidence of possible Zika virus infection in the 
United States and U.S. territories
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Infant Diagnostic Testing and Interpretation 
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Challenges with Diagnosis of Congenital Zika Infection
 Real time reverse–transcription polymerase chain reaction (rRT-PCR): 
– Positive can confirm congenital Zika virus infection
– Negative does not exclude infection- little is known about duration of 
viral shedding in congenital Zika virus infection
 Immunoglobulin M (IgM) results difficult to interpret because of false-
positive and false-negative results
 Antibody neutralization testing cannot distinguish maternal from infant 
antibodies
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Laboratory Testing of Infants with Possible Congenital 
Zika Virus Infection 
 Testing is recommended for:
– Infants born to mothers with laboratory evidence of Zika virus 
infection*
*Lab evidence of maternal Zika virus infection includes: Zika virus RNA detected by rRT-PCR 
OR positive Zika virus IgM with confirmatory neutralizing antibody titer 
– Infants with abnormal clinical or neuroimaging findings suggestive of 
congenital Zika syndrome and a maternal epidemiologic link†
suggesting possible transmission, regardless of maternal testing results 
† Epidemiologic link includes: Travel to/residence in an area of Zika virus transmission, 
OR sex with a partner who traveled to/resided in such area
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Congenital Zika Syndrome
 Congenital Zika syndrome is a recently recognized pattern of congenital 








Laboratory Testing of Infants with Possible Congenital 
Zika Virus Infection 
 Zika virus rRT-PCR should be performed on infant serum and urine
 Zika virus IgM antibody testing should be performed on infant serum
 If cerebrospinal fluid (CSF) is obtained for other purposes, rRT-PCR testing 
for Zika virus RNA and Zika virus IgM should be performed
 Lab testing of cord blood specimens is no longer recommended
 Testing should be performed within 2 days after birth
– If testing is performed later, distinguishing between congenital, 
perinatal and postnatal infection will be difficult
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Interpretation of Infant Zika Virus Testing 
Infant test results* Interpretation 
rRT-PCR IgM
Positive Positive or Negative Confirmed congenital Zika virus infection 
Negative Positive Probable congenital Zika virus infection+
Negative Negative Negative for congenital Zika virus infection+
Abbreviations: rRT-PCR = real-time reverse transcription-polymerase chain reaction; IgM = Immunoglobulin M 
*Infant serum, urine or cerebrospinal fluid
+Lab results should be interpreted in the context of timing of infection during pregnancy, maternal serology or clinical findings
consistent with congenital Zika syndrome, and any confirmatory testing with plaque reduction neutralization testing (PRNT)
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Plaque Reduction Neutralization Test (PRNT) 
 PRNT measures virus-specific neutralizing antibodies
– Used to confirm specificity of IgM antibodies against Zika virus
 PRNT cannot distinguish between maternal and infant antibodies
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Infant Plaque Reduction Neutralization Test (PRNT) 
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Infant Plaque Reduction Neutralization Test (PRNT) 
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Infant Plaque Reduction Neutralization Test (PRNT) 
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Infant Plaque Reduction Neutralization Test (PRNT) 
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Plaque Reduction Neutralization Test (PRNT) 
 If PRNT results at 18 months are negative: 
– Child considered to not have congenital Zika virus infection
 If PRNT results at 18 months are positive:
– Congenital Zika virus infection is presumed
• Postnatal infection cannot be excluded
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Zika Virus Testing of the Placenta
 Detection of Zika virus RNA in the placenta can confirm maternal 
infection
– Cannot distinguish between maternal and congenital infection
 Placental testing can be helpful to confirm maternal infection when 
maternal testing:
– Not previously performed
– Performed beyond 12 weeks after exposure
– Not definitive (e.g., Flavivirus Not Otherwise Specified)
 Clinical implications for infant with Zika virus RNA detected in the 
placenta are unknown, especially if infant testing is negative
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Maternal Testing Not Yet Performed
 For infants born to mothers with risk factors for Zika virus infection 
during pregnancy, but maternal testing not performed: 
– Perform maternal diagnostic testing
– Consider placental rRT-PCR testing
– Perform infant testing if abnormalities consistent with congenital Zika 
syndrome are present
 If an infant appears clinically well, infant lab testing for Zika virus 
infection can be deferred until maternal tests are available
– If concerns about infant follow-up, testing should be performed before 
hospital discharge
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Evaluation and Management of Infants with 
Congenital Zika Virus Infection 
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CDC and AAP Collaboration
 On July 21–22, CDC sponsored a meeting in collaboration with American 
Academy of Pediatrics (AAP), entitled “Clinical Evaluation and Management 
of Infants with Congenital Zika Virus Infection” involving:
– Specialties
• Audiology, clinical genetics, critical care, developmental and behavioral pediatrics, endocrinology, hospitalist medicine, 
infectious disease, lactation and infant feeding, maternal-fetal medicine, neonatology, neurology, nutrition, ophthalmology, 
orthopedics,  pediatrics, physical medicine and rehabilitation 
– Principal partners
• AAP, AAP Puerto Rico chapter, American Academy of Family Physicians, American Congress of Obstetricians and 
Gynecologists, Association of Maternal and Child Health Programs, Family Voices, March of Dimes, Parent to Parent, and the 
National Association of Pediatric Nurse Practitioners
– Other federal agencies
• Administration for Children and Families, Office of the Assistant Secretary for Preparedness and Response, Maternal & Child 
Health Bureau of the Health Resources and Services Administration, and National Institute of Child Health and Human 
Development, National Institutes of Health 
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Three Areas of Focus
1. Initial evaluation and testing of infants born to mothers with laboratory 
evidence of possible Zika virus infection during pregnancy
2. Outpatient management and follow-up of infants with laboratory 
evidence and with findings consistent with congenital Zika syndrome
3. Outpatient management and follow-up of infants with laboratory 
evidence of congenital Zika virus infection, but without findings consistent 




Interim Guidance for Evaluation and Testing: 
Infants with Possible Congenital Zika Virus Infection
http://www.cdc.gov/zika/pdfs/zika_peds.pdf
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Interim Guidance for Evaluation and Testing: 
Infants with Possible Congenital Zika Virus Infection
*Laboratory evidence of maternal Zika virus infection includes: (1) Zika virus RNA detected by real-time reverse transcription-polymerase chain reaction (rRT-PCR) in any clinical specimen; or (2) 
positive Zika virus IgM with confirmatory neutralizing antibody titers.  Mothers should be tested by rRT-PCR within 2 weeks of exposure or symptom onset, or by IgM within 2-12 weeks of 
exposure or symptom onset. Due to the decline in IgM antibody and viral RNA levels over time, negative maternal testing >12 weeks after exposure does not rule out maternal infection.
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Infants with Findings Consistent 
with Congenital Zika Syndrome
Initial Evaluation
• Consultation with: Neurologist, infectious disease specialist, ophthalmologist, endocrinologist, clinical geneticist
• Consider consultation with: Orthopedist, physiatrist and/or physical therapist, pulmonologist and/or otolaryngologist, lactation
specialist, nutritionist, gastroenterologist, or speech or occupational therapist 
• Perform ABR to assess hearing
• Perform complete blood count and metabolic panel, including liver function tests
• Provide family and supportive services
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Infants with Findings Consistent 
with Congenital Zika Syndrome
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Infants without Findings Consistent 
with Congenital Zika Syndrome
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Infants without Findings Consistent 
with Congenital Zika Syndrome
Reminder: Information on all 
pregnant women with 
laboratory evidence of Zika 
virus infection and their 
infants, regardless of infant 
test results, should be 










Family and Psychosocial Support
 Families and caregivers of infants with congenital Zika virus infection will 
require ongoing psychosocial support
 Health care providers should work closely with parents to ensure that the 
care plan is consistent with the infant’s needs and the family’s wishes
 Disproportionate burden of Zika virus infection might affect families with 
already limited access to medical care
– Language, cultural, and financial barriers to care
 Barriers to care for all affected infants and their families should be 
addressed through linkage to national, state and local health programs
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Resources for Clinicians
 Health care providers should work closely with the state, local, or territorial 
health department to ensure that all appropriate testing will be performed.  
 CDC maintains a 24/7 Zika consultation service for health officials and 
healthcare providers caring for infants born to pregnant women to assist 
with test interpretation and questions about clinical management
– To contact the service, call 770-488-7100 and ask for the Zika 





 Resources for Zika webpages






 Webcast of CDC meeting in collaboration with AAP
– http://www.cdc.gov/zika/hc-providers/webcast-clinicalevalution.html
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For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Thanks to our many collaborators and partners!
For clinical questions, please contact
ZikaMCH@cdc.gov
For U.S. Zika Pregnancy Registry questions, please contact
ZikaPregnancy@cdc.gov
To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Today’s webinar  will be archived
When:  A few days after the live call
What:  All call recordings (audio, webinar, and 
transcript)
Where:  On the COCA Call webpage 
http://emergency.cdc.gov/coca/calls/2016/callinfo_082316.asp
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Continuing Education  for COCA Calls
All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and 
AAVSB/RACE) for COCA Calls are issued online through the CDC Training 
& Continuing Education Online system (http://www.cdc.gov/TCEOnline/).
Those who participated in today’s COCA Call and who wish to receive 
continuing education  should complete the online evaluation by 
September 22, 2016 with the course code WC2286. Those who will 
participate in the on demand activity and wish to receive continuing 
education should complete the online evaluation between September 23 , 
2016 and August 22, 2018 will use course code WD2286. 
Continuing education certificates can be printed immediately upon 
completion of your online evaluation. A cumulative transcript of all 
CDC/ATSDR CE’s obtained through the CDC Training & Continuing 
Education Online System will be maintained for each user. 
Join the COCA Mailing 
List
Receive information about:
• Upcoming COCA Calls
• Health Alert Network notices
• CDC public health activations
• Emerging health threats
• Emergency preparedness and 
response conferences and 
training opportunities
http://emergency.cdc.gov/coca 
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for clinicians! “Like” 
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